Evidence map›Paper›PMID 32043067›Full record

ArticleInternational journal of reproductive biomedicine2019

The comparison of plasma fibronectin in term and preterm delivery: A cross-sectional, descriptive-analytical study.

Zahra Moradi, Parvin Moradi, Mohamad Hassan Meshkibaf, Mehrnoosh Aleosfoor, Mehdi Sharafi, Saeedeh Jafarzadeh

Open access · goldAbstract read
In one paragraph

Article in International journal of reproductive biomedicine, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact, top 99% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 2 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Zahra MoradiSchool of Nursing, Fasa University of Medical Sciences, Fasa, Iran.
Parvin MoradiDepartment of Obstetrics and Gynecology, Medical School, Fasa University of Medical Sciences, Fasa, Iran.
Mohamad Hassan MeshkibafDepartment of Clinical Biochemistry, Fasa University of Medical Sciences, Fasa, Iran.
Mehrnoosh AleosfoorSchool of Nursing, Fasa University of Medical Sciences, Fasa, Iran.
Mehdi SharafiNon-Communicable Diseases Research Center, Fasa University of Medical Sciences, Fasa, Iran.
Saeedeh JafarzadehSchool of Nursing, Fasa University of Medical Sciences, Fasa, Iran.
Fasa University of Medical Sciences · IR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundPreterm delivery is one of the main causes of infant death. Therefore, prediction of preterm delivery may eliminate a large number of prenatal complications.

objectiveThe present study aimed to understand if preterm delivery can be predicted by assessing maternal plasma fibronectin concentration. MATERIALS AND

methodsSerum samples from 105 pregnant women participating in this study were collected. The plasma fibronectin were measured at 24-28 wk of gestation and again at 32-36 wk of gestation. Unfortunately, only 65 of the 105 pregnant women, returned for the second sampling. The plasma fibronectin was analyzed using ELISA method and its concentration in term and preterm deliveries was compared. The delivery dates of all the women were also recorded.

resultsOut of 105 pregnant women, 28 delivered preterm (26.7%). The Plasma fibronectin concentrations in women with preterm delivery were higher than in those who delivered at term (p = 0.001). Accordingly, Plasma fibronectin concentrations were significantly higher in the second serum samples (p = 0.01). Plasma fibronectin concentrations was also higher in obese women and in those suffering from preeclampsia (p = 0.12) and gestational diabetes (p = 0.81).

conclusionPlasma fibronectin concentrations test could be used as an optional screening test for preterm delivery at 28 to 34 wk of gestation in pregnant women who prefer to avoid vaginal sampling.

Indexed as

FibronectinMaternal serum screening tests.Premature birth

Identifiers

PMID32043067
PMCPMC6996127
OpenAlexW3001321088

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.